Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease.

Asadzadeh-Aghdaei H, Mashayekhi K, Koushki K, Azimzadeh P, Rostami-Nejad M, Amani D, Chaleshi V, Haftcheshmeh SM, Sahebkar A, Zali MR.

J Cell Biochem. 2019 May 8. doi: 10.1002/jcb.28844. [Epub ahead of print]

PMID:
31069840
2.

The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.

Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydłowska A, Kroll-Balcerzak R, Balcerzak A, Iwoła M, Michalak M, Komarnicki M.

Thromb Res. 2015 Feb;135(2):272-80. doi: 10.1016/j.thromres.2014.11.006. Epub 2014 Nov 15.

PMID:
25559461
3.

Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N.

Trop Gastroenterol. 2011 Oct-Dec;32(4):279-84.

PMID:
22696908
4.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

5.

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

Lamy M, Palazzo P, Agius P, Chomel JC, Ciron J, Berthomet A, Cantagrel P, Prigent J, Ingrand P, Puyade M, Neau JP.

Cerebrovasc Dis. 2017;44(3-4):97-104. doi: 10.1159/000471891. Epub 2017 Jun 14.

PMID:
28609766
6.

Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?

Zerjavic K, Zagradisnik B, Stangler Herodez S, Lokar L, Glaser Krasevac M, Kokalj Vokac N.

Acta Haematol. 2010;124(1):49-56. doi: 10.1159/000314645. Epub 2010 Jul 9.

PMID:
20616539
7.

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M.

J Thromb Haemost. 2007 Jan;5(1):55-61. Epub 2006 Oct 20.

8.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, Kim DK.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.

PMID:
21435189
9.

Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.

Benati M, Montagnana M, Danese E, De Matteis G, Veneri D, Paviati E, Guidi GC.

Clin Chem Lab Med. 2015 Jun;53(7):1005-11. doi: 10.1515/cclm-2014-0858.

PMID:
25527813
10.

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.

Karaköse S, Oruç N, Zengin M, Akarca US, Ersöz G.

Turk J Gastroenterol. 2015 Jan;26(1):42-8. doi: 10.5152/tjg.2015.5738.

11.
12.

Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.

Rai P, Kumar P, Mishra S, Aggarwal R.

Indian J Gastroenterol. 2016 Sep;35(5):366-371. Epub 2016 Sep 16.

PMID:
27633031
13.

A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.

Poodt J, Fijnheer R, Walsh IB, Hermans MH.

Hematol Oncol. 2006 Dec;24(4):227-33.

PMID:
17006961
14.

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Hematology. 2008 Apr;13(2):71-6. doi: 10.1179/102453308X315960.

PMID:
18616871
15.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
16.

JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.

da Silva RR, Domingues Hatzlhofer BL, Machado CG, Lima AS, de Albuquerque DM, dos Santos MN, Fertrin KY, Costa FF, Araújo Ada S, Bezerra MA.

Genet Test Mol Biomarkers. 2012 Jul;16(7):802-5. doi: 10.1089/gtmb.2011.0272. Epub 2012 Feb 3.

PMID:
22304488
17.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97. Epub 2014 May 26.

18.

JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.

Ar MC, Hatemi G, Ekizoğlu S, Bilgen H, Saçli S, Buyru AN, Soysal T, Ülkü B, Yazici H.

Clin Appl Thromb Hemost. 2012 Jul;18(4):421-6. doi: 10.1177/1076029611427440. Epub 2011 Dec 26.

PMID:
22203033
19.

Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation.

Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T, Belambri SA, Fay M, Cassinat B, Gougerot-Pocidalo MA, Dang PM, El-Benna J.

Haematologica. 2013 Oct;98(10):1517-24. doi: 10.3324/haematol.2012.082560. Epub 2013 Aug 23.

Supplemental Content

Support Center